Gubra A/S is a biotechnology company specializing in preclinical contract research and peptide-based drug discovery, primarily targeting metabolic and fibrotic diseases. Headquartered in Hørsholm, Den... Gubra A/S is a biotechnology company specializing in preclinical contract research and peptide-based drug discovery, primarily targeting metabolic and fibrotic diseases. Headquartered in Hørsholm, Denmark, it focuses on the early stages of drug development, leveraging proprietary platforms like StreaMLine, AI, machine learning, and high-throughput screening to advance peptide therapeutics. The company's robust R&D pipeline spans metabolic, endocrine, fibrotic, inflammatory, CNS, respiratory, and women's health disorders, featuring internal programs such as urocortin-2 analogues for high-quality weight loss, dual orexin receptor agonists for narcolepsy, GLP-1 receptor agonists, and PTH receptor agonists for hypoparathyroidism. Gubra also collaborates with partners like AbbVie, Boehringer Ingelheim, and Amylyx Pharmaceuticals on obesity treatments, including amylin analogs and triple agonists in clinical stages. With operations emphasizing translational in vivo models and global presence, particularly in North America and the Nordic region, Gubra plays a key role in innovating therapies for chronic conditions like obesity, diabetes, and rare endocrine disorders.